

## Rectal Clinical Trials

To go back to the main page, click [here](#)

| S.No | Drug Name                         | Biological Name  | Developer  | Current Development Phase | Additional Information  | Start Date | Completion Date | Source                 |
|------|-----------------------------------|--|--|---------------------------|---|------------|-----------------|------------------------|
| 11   | -                                 | carcinoembryonic antigen RNA-pulsed DC cancer vaccine                  | Duke University, National Cancer Institute (NCI)         | I                         | Phase I trial to study the effectiveness of biological therapy in treating patients who have metastatic cancer that has not responded to previous treatment.  | 2000       | 2009            | <a href="#">Source</a> |
| 12   | -                                 | carcinoembryonic antigen RNA-pulsed DC cancer vaccine                  | Duke University, National Cancer Institute (NCI)         | I/II                      | Phase I/II trial to study the effectiveness of immunotherapy with CEA-treated white blood cells in treating patients with resected liver metastases from colon cancer.  | 1999       | 2009            | <a href="#">Source</a> |
| 13   | -                                 | QS21, ras peptide cancer vaccine                                       | Fox Chase Cancer Center, National Cancer Institute (NCI) | I                         | Phase I trial to study the effectiveness of vaccine therapy plus QS21 in treating patients who have advanced pancreatic or colorectal cancer.   | -          | -               | <a href="#">Source</a> |
| 14   | GI-4000                           | -  | GlobelImmune   | II                        | The purpose of this study is to test the safety of GI-4000 and see what effects (good and bad) it has against cancer over time  | 2010       | 2013            | <a href="#">Source</a> |
| 15   | -                                 | Allogeneic whole epithelial tumor cells, DNP-conjugated and irradiated | Hadassah Medical Organization                            | I/II                      | This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with colorectal, gastric, ovarian, breast or lung epithelial cancer | -          | -               | <a href="#">Source</a> |
| 16   | Endoxana, Leukine, IMA910, Aldara | -  | Immatics Biotechnologies GmbH                            | I/II                      | This study is being conducted in order determine whether IMA910 as single agent with GM-CSF as adjuvant following pre-treatment with low-dose cyclophosphamide is safe and shows sufficient anti-tumour effectiveness in patients with advanced CRC to warrant further development                                  | 2008       | 2012            | <a href="#">Source</a> |
| 17   | -                                 | PSMA/PRAE  | MannKind Corporation                                     | I                         | Completed<br>The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.  | 2007       | 2009            | <a href="#">Source</a> |
| 18   | MEDI-547                          | -  | MedImmune/Anza   | I                         | Terminated.<br>Purpose was: To determine the safety, tolerability, and the highest dose of this drug given once every 3 weeks or once every week, (per 21 day cycle) in adult subjects with relapsed or refractory  | 2009       | 2010            | <a href="#">Source</a> |

|    |  |   |                                 |             |   |      |         |                        |
|----|--|---|---------------------------------|-------------|---|------|---------|------------------------|
|    |  |   |                                 |             | solid tumors  |      |         |                        |
| 19 | -  | V930 /V932                              | Merck                           | I           | Completed.<br>Treatment of patients with cancer types known to express the HER-2 and/or CEA tumor antigens  | 2007 | 2009    | <a href="#">Source</a> |
| 20 | -  | V934/V935                               | Merck                           | I           | Completed.<br>This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.  | 2008 | 2011    | <a href="#">Source</a> |
| 21 | Detox-B adjuvant, ras peptide cancer vaccine | -                                       | National Cancer Institute (NCI) | I           | Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.   | 1995 | Ongoing | <a href="#">Source</a> |
| 22 | Detox-B adjuvant, ras peptide cancer vaccine | -                                       | National Cancer Institute (NCI) | I           | Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.   | 1995 | Ongoing | <a href="#">Source</a> |
| 23 | -  | Interleukin-2                           | National Cancer Institute (NCI) | II          | Phase II trial to study the effectiveness of a vaccine made with the patients' white blood cells mixed with tumor proteins in treating patients who have advanced cancer.   | -    | -       | -                      |
| 24 | -  | Aldesleukin, ras peptide cancer vaccine | National Cancer Institute (NCI) | I/II        | Phase I/II trial to study the effectiveness of vaccine therapy with or without interleukin-2 in treating patients who have locally advanced or metastatic colorectal cancer.  | 1999 | Ongoing | <a href="#">Source</a> |
| 25 | Detox-B adjuvant, ras peptide cancer vaccine | -                                       | National Cancer Institute (NCI) | I           | Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.   | 1995 | Ongoing | <a href="#">Source</a> |
| 26 | Detox-B adjuvant, ras peptide cancer vaccine | -                                       | National Cancer Institute (NCI) | I           | Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune adjuvant in treating patients who have colon, pancreatic, or lung cancer.   | 1995 | Ongoing | <a href="#">Source</a> |
| 27 | -  | ONT-10                                  | Oncothyreon                     | Preclinical | -   | -    | -       | -                      |
| 28 | Interferon-alpha                             | Trovax                                  | Oxford BioMedica                | II          | Study has been completed  | 2006 | 2008    | <a href="#">Source</a> |
| 29 | -  | AdhTAP                                  | TapImmune                       | Preclinical | -   | -    | -       | -                      |
| 30 | -  | OncoVAX autologous vaccine              | Vaccinogen                      | III         | Available in Netherlands/Switzerland<br>Possible U.S. and E.U. approvals in 2014  | -    | -       | -                      |
| 31 | -  | CEA DNA Cancer Vaccine                  | Vical/Merck                     | I           | The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers. | 2007 | 2009    | -                      |

To go back to the main page, click [here](#)